Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase II Study of Chemotherapy with Anguidine for Solid Tumors

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed 18 and over SEG-77ST219
SEG-77ST0102

Objectives

I.  Determine the efficacy of anguidine in a Phase II study of prognostically 
poor solid tumors that have been untreated or have been refractory to previous 
therapy.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients at least 18 years old with 
tissue diagnosis of solid tumor, considered incurable, with at least one 
measurable lesion other than in bone.  (Closed to colorectal patients in 
October 1978, to patients with melanoma in November 1979, to gastrointestinal 
cancer patients and those with non-small cell lung cancer in July 1980, and to 
patients with small cell lung cancer and myeloma in January 1981.)  A 
Karnofsky performance status of 40% or higher, recovery from any previous 
therapy, and adequate hematological, hepatic and renal functions are required.

Expected Enrollment

Protocol closed March 1981.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.

Published Results

Adler SS, Lowenbraun S, Birch B, et al.: Anguidine: a broad phase II study of the Southeastern Cancer Study Group. Cancer Treat Rep 68 (2): 423-5, 1984.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Southeastern Cancer Study Group

George A. Omura, MD, Protocol chair
Ph: 205-444-4617

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.